

This CME/CE/CEU accredited supplement is jointly provided by



## The Emerging Role of Molecular Testing in Ovarian Cancer

A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

**Release date:** October 19, 2017

**Estimated time to complete activity:** 1.0 hour

**Expiration date:** October 18, 2018

### **Annenberg Center for Health Sciences at Eisenhower**

39000 Bob Hope Drive, Dinah Shore Bldg.

Rancho Mirage, CA 92270

Voice: 760-773-4500

Fax: 760-773-4513

E-mail: [contactce@annenberg.net](mailto:contactce@annenberg.net)

### **Journal of the Advanced Practitioner in Oncology**

94 North Woodhull Road

Huntington, NY 11743

Voice: 631-692-0800

Fax: 631-692-0805

E-mail: [claudine@harborsidepress.com](mailto:claudine@harborsidepress.com)

© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

This supplement is supported by an educational grant from AstraZeneca.

### **Faculty**

**Courtney B. Cortez, NP**, Indiana University Simon Cancer Center—IU Health

**Cynthia L. Hunter, MS, LCGC**, Indiana University Health

**Patrick J. Kiel, PharmD, BCPS, BCOP**, Indiana University School of Medicine, Indiana University Simon Cancer Center—IU Health

**Jeanne M. Schilder, MD**, Indiana University School of Medicine, Indiana University Simon Cancer Center—IU Health

### **Activity Rationale and Purpose**

A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. Precision medicine seeks to select the most effective treatment option for each individual patient's tumor, given at the appropriate time in the life cycle of the disease, and predicated upon an understanding of the specific molecular nature of the tumor with the ultimate goal of improving survival and quality of life. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of ovarian cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy.

### **Intended Audience**

The activity's target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

## Learning Objectives

After completing this educational activity, participants should be able to:

1. Recognize the differences between prognostic and predictive genomic markers in practice, and the types of cancer in which indicative markers are currently being used in practice.
2. Relate NCCN guideline recommendations regarding molecular testing in ovarian cancer, including monitoring for BRCA, and the advantages and potential limitations of findings to treatment planning.
3. Describe the goals and challenges for the future broader introduction and implementation of molecular testing into routine cancer patient care and clinical trials that may provide translational insights.

## Continuing Education

**Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.**



**Physicians.** This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



**Nurses.** The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.



**Pharmacists.** The knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-094-H01-P. This program is designated for up to 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit.

## Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

## Disclosures

### FACULTY

**Courtney B. Cortez, NP**, has nothing to disclose.

**Cynthia L. Hunter, MS, LCGC**, has nothing to disclose.

**Patrick J. Kiel, PharmD, BCPS, BCOP**, has served on speakers bureaus for Celgene, Gilead, and Takeda.

**Jeanne M. Schilder, MD**, has been an employee (contract ended January 2017) and significant shareholder (fully divested) of Eli Lilly & Co.

### ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER

**John Bayliss, VP, Business Development**, spouse is an employee of Amgen, Inc; **Charles Willis, Director, Continuing Education**, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

### LEAD NURSE PLANNER

**Dorothy Caputo, MA, BSN, RN**, has nothing to disclose.

### PLANNERS

**Chris Cherry** has nothing to disclose.

**Jeannine Coronna** has nothing to disclose.

**Joseph Cupolo** has nothing to disclose.

**Claudine Kiffer** has nothing to disclose.

**Lynn Rubin** has nothing to disclose.

**Pamela Hallquist Viale, RN, MS, CNS, ANP**, has nothing to disclose.

**Annie Yueh** has nothing to disclose.

### CONTENT REVIEWERS

**Paula Anastasia, RN, MN, AOCN®**, has served on speakers bureaus for Clovis, Genentech, and Merck.

## Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

## Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

## How to Earn Credit

To access the learning assessment and evaluation form online, visit <http://surveys.edmeasures.com/s3/Ovarian-Cancer-Print-Post-Test>

**Statement of Credit:** Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.